Exhibit 99.1

                                [OBJECT OMITTED]
                                 (Sangui Biotech
                         International, Inc. Letterhead)



SANGUI AND MERCATURA SIGN LETTER OF INTENT TO MARKET ANTI-AGING FORMULATION

Witten, May 6, 2004 - SanguiBioTech GmbH, Witten, Germany, a wholly owned
subsidiary of SanguiBioTech International, Inc. (NASD OTCBB: SGBI), and
Mercatura Cosmetics Biotech AG, Achim, Germany, have signed a letter of intent
aiming at marketing "Pure Moisture", an anti-aging nano-formulation developed by
Sangui. Under the proposed agreement Sangui will license to Mercatura the
exclusive right to sell the nano-emulsion in German and international markets.
Mercatura plans to include this product under its "Wunderkind" brand, jointly
marketed by Mercatura and German top designer Wolfgang Joop. "Pure moisture"
recently received top marks in skin tolerance and moisturization by Dermatest,
renowned independent German dermatological research and testing institute.




For more information:
Joachim Fleing
Phone: +49 (160) 741 27 17
Fax: +49 (2302) 915 191
e-mail: fleing@sangui.de




This news release includes  statements,  other than historical fact, that may be
deemed  forward-looking.  These  statements  may be accompanied by words such as
"believe,"  "estimate,"  "project,"  "expect,"  "anticipate,"  or "predict" that
conveys the uncertainty of future events or outcomes. These statements are based
on assumptions that the Company believes are reasonable;  however,  many factors
could cause the Company's actual results in the future to differ materially from
the  forward-looking  statements  made herein and in any other documents or oral
presentations  made by, or on behalf of, the Company.  Important  factors  which
could cause actual results to differ  materially  from those in  forward-looking
statements  include,  among others, the ability to obtain additional  financing,
which is not assured; rapid technological  developments and changes; problems in
developments  of the  Company's  products;  price  and  product  competition  by
competitors; general economic conditions; and factors discussed in the Company's
SEC filings.  Shareholders are cautioned that the forward-looking statements are
not guarantees of future performance and that developments  different from those
projected in the  forward-looking  statements  can be expected.  Sangui does not
intend (and is not legally  obligated)  to update  publicly any  forward-looking
statements.